- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04901377
A Study to Gather Information About User Satisfaction in Women in Russia Who Take Estradiol Valerate/Dienogest (Q-SWAN)
A Prospective Multicenter Non-interventional Study to Evaluate User Satisfaction With Estradiol Valerate/ Dienogest in Real Clinical Practice to be Conducted in Russia
Researchers want to learn more about user satisfaction in women in Russia who take estradiol valerate/ dienogest as a contraceptive in real conditions.
Estradiol valerate/ dienogest is a form of birth control. This is also known as a combined oral contraceptive (COC). Earlier studies showed that estradiol valerate/ dienogest has high level of protection from unplanned pregnancy. It is available for doctors to prescribe to women who want to take an oral contraceptive.
Estradiol valerate/ dienogest as a combined oral contraceptive (COC), works by stopping a process called ovulation. This is the process by which the ovaries release an egg. COCs are commonly used by young women to prevent pregnancy.
The researchers in this study will collect information from young women (18-35 years of age) in Russia who will start taking estradiol valerate/ dienogest.
The main purpose of this study is to find out about the women's satisfaction with taking estradiol valerate/ dienogest. To do this, the researchers will ask "how satisfied are you with the birth control method used during the study?". They will ask this question after the women have taken estradiol valerate/ dienogest for 3 and 6 months. The women willanswer this question using a rating scale ranging from 1 to 5, with 1 meaning "very dissatisfied" and 5 meaning "very satisfied".
This study will include young women (18-35 years of age) who want to use oral contraceptives and have been prescribed estradiol valerate/ dienogest by their doctor. None of the women in the study will have taken estradiol valerate/ dienogest within 1 month of joining the study.
In this study, it is expected that each woman will visit her study site 3 times. Each woman will be in the study for up to 6 months. All of the women will take estradiol valerate/ dienogest as prescribed by their doctors. There will be no other required procedures or treatments in this study which is not be used in usual practice.
During the study, the women will answer a question about how satisfied they are with estradiol valerate/ dienogest. They will also respond to some questionnaires. These will include a questionnaire about their menstrual bleeding patterns, sexual function. The doctors will:
- ask the women about any medical conditions they may have and what other contraceptives they took before they joined the study
- check the women's blood pressure and pulse rate
- ask a question about woman's intention to continue to use estradiol valerate/ dienogest and the reasons for discontinuation of estradiol valerate/ dienogest if it has happened
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Bayer Clinical Trials Contact
- Phone Number: (+)1-888-84 22937
- Email: clinical-trials-contact@bayer.com
Study Locations
-
-
-
Multiple Locations, Russian Federation
- Many locations
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age from 18 to 35 y.o.
- Indications for administration of estradiol valerate/ dienogest for the purpose of oral contraception.
- Patients who did not take estradiol valerate/ dienogest for at least one month before enrollment into the study.
- Signed informed consent to participate in the study
Exclusion criteria
- Participation in an investigational program with interventions outside of routine clinical practice.
- Contraindications to estradiol valerate/ dienogest according to the local market authorization.
- Any medical and non-medical reasons that according to the physician's judgment may prevent patient's participation in the non-interventional study.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Combined oral contraception: Estradiol valerate / Dienogest
Young women (18-35 years of age) using estradiol valerate / dienogest in real clinical practice.
|
Combined hormonal contraceptive (combined oral contraceptives, COCs)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
User satisfaction rates
Time Frame: up to 6 months
|
User satisfaction rates assessed by subjects using an overall satisfaction rating (5-point Likert item) with the following question: "How satisfied are you with the birth control method used during the study?" Answers include: 1 - very dissatisfied; 2 - dissatisfied; 3 - neither satisfied nor dissatisfied; 4 - satisfied; 5 - very satisfied. Subjects selecting answers #4 or #5 (i.e., subjects expressing satisfaction) will count toward the overall satisfaction rate. |
up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Satisfaction rates assessed by physicians
Time Frame: up to 6 months
|
Satisfaction rates assessed by physicians using an overall satisfaction rating (5-point Likert item) with the following question: "How satisfied are you with the birth control method used during the study?" Answers include: 1 - very dissatisfied; 2 - dissatisfied; 3 - neither satisfied nor dissatisfied; 4 - satisfied; 5 - very satisfied. Physicians selecting answers #4 or #5 (i.e., physicians expressing satisfaction) will count toward the overall satisfaction rate. |
up to 6 months
|
Bleeding profile
Time Frame: up to 6 months
|
The bleeding profile during the previous 3 months and during therapy (visits 2,3), self-reported: regularity (regular, periodically absent, permanently absent); maximum bleeding duration (1-2 days, 3-5 days, 6-7 days, 8 days and more); maximum bleeding intensity (spotting, light bleeding, normal bleeding, heavy bleeding); painful bleeding (yes/ no); inter-menstrual bleeding (yes/ no).
|
up to 6 months
|
Sexual function using FSFI
Time Frame: up to 6 months
|
Sexual function using "Female Sexual Function Index" (FSFI).
|
up to 6 months
|
Sexual function using ASQ
Time Frame: up to 6 months
|
Sexual function using Atrophy Symptom Questionnaire (ASQ): dryness; sensitivity; irritation; dyspareunia; vaginal discharge (each symptom will be assessed with the following scale: 0 - normal, 1 - mild, 2 - moderate, 3 - severe).
|
up to 6 months
|
Reasons for discontinuation
Time Frame: up to 6 months
|
up to 6 months
|
|
Patient's intentions to continue to take estradiol valerate/ dienogest
Time Frame: up to 6 months
|
yes / no
|
up to 6 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Antineoplastic Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Estrogens
- Hormone Antagonists
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Hormonal
- Contraceptive Agents, Male
- Estradiol
- Estradiol 17 beta-cypionate
- Estradiol 3-benzoate
- Polyestradiol phosphate
- Dienogest
Other Study ID Numbers
- 21768
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oral Contraception
-
Columbia UniversityCenters for Disease Control and PreventionCompletedOral ContraceptionUnited States
-
BayerCompletedContraception | Ovulation Inhibition | Contraceptives, OralUnited States
-
Health DecisionsEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedFocus: Estrogen-free Oral ContraceptionUnited States
-
Thomas Cherpes, DVM, MDEunice Kennedy Shriver National Institute of Child Health and Human Development...TerminatedInitiation of Oral Contraception (OC) | Initiation of Depo-Provera (DMPA) | Initiation of Mirena (LNG-IUD)United States
-
Virginia Commonwealth UniversityCompletedPregnancy Related | Contraception | Contraception Behavior | Contraception Use
-
BayerCompletedContraception | Neural Tube Defects | Oral Contraceptives (OC)United States
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Janssen Pharmaceutica N.V., BelgiumCompleted
Clinical Trials on Estradiol valerate/ Dienogest
-
Laboratorios Andromaco S.A.Completed
-
BayerCompletedMetrorrhagiaUnited States, Canada
-
Bagcilar Training and Research HospitalKocaeli Derince Education and Research Hospital; Suleymaniye Birth And Women...UnknownOvarian ReserveTurkey
-
Helsinki University Central HospitalOulu University HospitalCompleted
-
BayerCompletedMetrorrhagiaSweden, Germany, Poland, Finland, Australia, Czech Republic, Hungary, Netherlands, Ukraine, United Kingdom
-
BayerCompletedPrimary DysmenorrheaItaly, Chile, United States, Philippines, Canada, Germany
-
Pharbil Waltrop GmbHCompletedFocus: BioequivalenceGermany
-
EstetraCompleted
-
Adana Numune Training and Research HospitalCompletedPrimary Dysmenorrhea
-
Laboratorios Andromaco S.A.Completed